Australia's CSL up as Morgan Stanley remains positive on plasma division

** Shares of CSL CSL rise as much as 1.8% to A$178.47, set to snap two straight sessions of losses

** Morgan Stanley sees a favourable medium- to long-term outlook in demand for immunoglobulin (Ig), a component found in blood plasma

** Notes distributed volume of Ig in the U.S. has increased strongly over time, with high single-digit annual growth recorded over the past 3, 10 and 15 years

** Brokerage sees headroom for growth in the U.S. across various therapies, including cell therapy; also sees scope for increased in ex-U.S. markets

** MS sees potential for Ig outlook alongside yield initiatives to support a gross margin recovery for CSL Behring, co's plasma segment

** Brokerage retains "overweight" tag, price target A$248

** Stock down 37.3% YTD, including the day's moves